Dashboard
Analysis
Charting
Screener
Resources
Settings
NYSE-PFE
Sep '20
Jul '21
Apr '22
Dec '22
Oct '23
Jun '24
Mar '25
Primary Care Revenue
27,793
29,207
Specialty Care Revenue
17,214
17,092
Oncology Revenue
16,462
16,252
Global Pharmaceuticals Business (Biopharma) Revenue
61,469
62,551
Business Innovation (Pfizer CentreOne) Revenue
1,255
1,196
Other Revenue
61
86
Total Revenue
62,785
63,833
United States Revenue
37,180
38,553
Developed Markets Revenue
16,550
16,266
Emerging Markets Revenue (Post-FY2023 Reporting)
9,055
9,014
Other Revenue by Geography
—
Total Revenue by Geography
Developed Europe Revenue
Developed Rest of World Revenue
Emerging Markets Revenue
International Revenue
25,605
25,280
Global Pharmaceuticals Business (Biopharma) Earnings
28,804
28,604
Other Business Activities Earnings
-8,166
-6,559
Other EBT
-11,485
-11,510
Total EBT
9,153
10,535
Comirnaty Direct Sales and Alliance Revenue
5,480
5,751
Eliquis Alliance Revenue and Direct Sales
7,773
7,375
Prevnar Revenue
Paxlovid Revenue
2,870
4,348
Prevnar Family Revenue
6,343
6,404
Nurtec ODT/Vydura Revenue
1,411
1,336
Abrysvo Revenue
751
828
Vyndaqel Family Revenue
6,236
6,092
Xeljanz Revenue
1,113
1,121
Ibrance Revenue
4,178
4,208
Vaccines Revenue
Internal Medicine Revenue
Hospital Revenue
Inflammation & Immunology Revenue
Rare Disease Revenue
